Search research articles
Contact Us
Filters
Showing results (221-230 of 279) with videos related to
Page
of 28
Sort By:
Prostate Cancer and Prostatic Diseases
|
March 22, 2021
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer
Hui-Ming Lin, Kevin Huynh, Manish Kohli, et al.
International Journal of Cancer
|
July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer
Hui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 1999
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience
C Tropé, T Hogberg, J Kaern, et al.
Ebiomedicine
|
December 9, 2025
Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells
Neil Portman, Blossom Mak, Nicole Yeung, et al.
Nature Communications
|
November 26, 2014
ERG induces taxane resistance in castration-resistant prostate cancer
Giuseppe Galletti, Alexandre Matov, Himisha Beltran, et al.
JAMA Network Open
|
August 9, 2024
Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy
Tiffany Li, Hannah C Timmins, Fawaz M Mahfouz, et al.
European Urology Focus
|
May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Edmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
International Journal of Cancer
|
October 6, 2018
An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy
Alison Y Zhang, Karen Chiam, Ygal Haupt, et al.
Therapeutic Advances in Medical Oncology
|
April 25, 2022
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
Ciara Conduit, Blossom Mak, Wenjia Qu, et al.
Cancer Research
|
July 23, 2003
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse
Susan M Henshall, Daniel E H Afar, Jordan Hiller, et al.
Page
of 28
Search research articles
Search
Showing results (221-230 of 279) with videos related to
Sort By:
Page
of 28
Prostate Cancer and Prostatic Diseases
|
March 22, 2021
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer
Hui-Ming Lin, Kevin Huynh, Manish Kohli, et al.
International Journal of Cancer
|
July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer
Hui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 1999
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience
C Tropé, T Hogberg, J Kaern, et al.
Ebiomedicine
|
December 9, 2025
Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells
Neil Portman, Blossom Mak, Nicole Yeung, et al.
Nature Communications
|
November 26, 2014
ERG induces taxane resistance in castration-resistant prostate cancer
Giuseppe Galletti, Alexandre Matov, Himisha Beltran, et al.
JAMA Network Open
|
August 9, 2024
Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy
Tiffany Li, Hannah C Timmins, Fawaz M Mahfouz, et al.
European Urology Focus
|
May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Edmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
International Journal of Cancer
|
October 6, 2018
An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy
Alison Y Zhang, Karen Chiam, Ygal Haupt, et al.
Therapeutic Advances in Medical Oncology
|
April 25, 2022
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
Ciara Conduit, Blossom Mak, Wenjia Qu, et al.
Cancer Research
|
July 23, 2003
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse
Susan M Henshall, Daniel E H Afar, Jordan Hiller, et al.
Page
of 28